The relevant quote is that the 9 month 2-73 results "shows a potential treatment benefit of several points [compared to historical controls]."
In graphs, this means the 2-73 line is dropping but is still several points above the line for the typical AD population. I think this should get us BP interest to partner on a Phase 2/3. We'll see.
Market Data 
Markets 
AI
